First and only oral on-demand treatment for HAE approved by US FDA

A new medicine for HAE, called Ekterly (sebeltralstat), has been approved by the regulatory authorities in the USA, and can begin to be prescribed to people with HAE immediately.

Ben Palleiko, CEO of KalVista, said: “The FDA approval of Ekterly is a defining moment for people living with HAE. Ekterly enables people to treat attacks the moment symptoms begin, wherever they are. This approval affirms the strength of our science and deep commitment to the HAE community. I am profoundly grateful to the KalVista team for their dedication and perseverance, and to the patients and healthcare providers, as well as the HAEA and HAEi, for making this possible.”

Anthony J. Castaldo, Chief Executive Officer of the US Hereditary Angioedema Association, said: “As the first orally administered on-demand therapy for HAE attacks, Ekterly provides patients and physicians with an important and welcome advance in HAE treatment options.”

(Source: KalVista)